Demei Zhu
YOU?
Author Swipe
View article: Antimicrobial resistance profile of clinical isolates from hospitals across China: CHINET 2024 surveillance report
Antimicrobial resistance profile of clinical isolates from hospitals across China: CHINET 2024 surveillance report Open
This study aimed to monitor clinical isolate susceptibility to antimicrobial agents in healthcare facilities in 31 provinces or cities of China in 2024. Antimicrobial susceptibility of clinical isolates from 74 hospitals was tested using d…
View article: Trends in antimicrobial resistance in Enterobacterales isolated from children: data from the China Antimicrobial Surveillance Network (CHINET) from 2015–2021
Trends in antimicrobial resistance in Enterobacterales isolated from children: data from the China Antimicrobial Surveillance Network (CHINET) from 2015–2021 Open
Antimicrobial resistance poses a significant threat to global public health, especially for Enterobacterales. In this study, we investigated the distribution and antimicrobial resistance of Enterobacterales in children in the China Antimic…
View article: A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients
A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients Open
Nemonoxacin 500 mg IV once daily for 7-14 days is effective and safe and non-inferior to levofloxacin for treating CAP in adult patients.
View article: Changing antimicrobial resistance profile of Enterobacter spp. isolates in hospitals across China: a seven-year analysis from the CHINET antimicrobial resistance surveillance program (2015–2021)
Changing antimicrobial resistance profile of Enterobacter spp. isolates in hospitals across China: a seven-year analysis from the CHINET antimicrobial resistance surveillance program (2015–2021) Open
Antimicrobial resistance poses a global threat to human health. Analyzing monitoring data on antimicrobial resistance can assist clinicians in making strategic decisions and promptly identifying outbreaks of antimicrobial-resistant organis…
View article: Current status and trends of antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 2018 to 2022
Current status and trends of antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 2018 to 2022 Open
Antimicrobial resistance (AMR) is a pressing issue in China, with antibiotic therapy becoming less effective against bacterial infections. To address this challenge, the China Antimicrobial Surveillance Network (CHINET) was established in …
View article: Setting of the tentative epidemiological cut-off values of contezolid for<i>Staphylococcus aureus</i>,<i>Enterococcus faecalis</i>,<i>Enterococcus faecium</i>,<i>Streptococcus pneumoniae</i>and<i>Streptococcus agalactiae</i>
Setting of the tentative epidemiological cut-off values of contezolid for<i>Staphylococcus aureus</i>,<i>Enterococcus faecalis</i>,<i>Enterococcus faecium</i>,<i>Streptococcus pneumoniae</i>and<i>Streptococcus agalactiae</i> Open
Objectives To set the tentative epidemiological cut-off values (TECOFFs) of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae based on the distributions…
View article: Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia
Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia Open
Introduction: Nemonoxacin is an innovative quinolone antibiotic for treatment of community-acquired pneumonia (CAP). As more data are available from clinical studies, it is necessary to perform an integrative pharmacokinetic/pharmacodynami…
View article: Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of <i>Enterobacterales</i> and Pseudomonas aeruginosa
Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of <i>Enterobacterales</i> and Pseudomonas aeruginosa Open
Multidrug-resistant Enterobacterales and P. aeruginosa strains have become a global public threat, with the emergence and prevalence of plasmid-mediated extended-spectrum β-lactamases (ESBLs), AmpC cephalosporinases, and carbapenemases dis…
View article: Multicenter Antimicrobial Resistance Surveillance of Clinical Isolates from Major Hospitals — China, 2022
Multicenter Antimicrobial Resistance Surveillance of Clinical Isolates from Major Hospitals — China, 2022 Open
Multidrug-resistant bacteria remain a significant public health challenge in clinical antimicrobial treatment. To effectively address bacterial resistance, it is essential to enhance both bacterial resistance surveillance and the prudent u…
View article: A multicenter investigation of 2,773 cases of bloodstream infections based on China antimicrobial surveillance network (CHINET)
A multicenter investigation of 2,773 cases of bloodstream infections based on China antimicrobial surveillance network (CHINET) Open
Background Bloodstream infections (BSIs), especially hospital-acquired BSIs, are a major cause of morbidity and mortality. However, the details about the pathogens and antimicrobial resistance profile of BSIs across China are still lacking…
View article: Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)
Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018) Open
View article: Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 <i>Staphylococcus</i> and 1,068 <i>Enterococcus</i> Species Isolates from China: Updated Report of the CHINET Study 2019
Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 <i>Staphylococcus</i> and 1,068 <i>Enterococcus</i> Species Isolates from China: Updated Report of the CHINET Study 2019 Open
Antimicrobial resistance has become a severe threat to global public health. According to statistics, nearly 700,000 people die from bacterial infections worldwide (J.
View article: <i>In Vitro</i> Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019
<i>In Vitro</i> Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019 Open
Enterobacterales , Pseudomonas aeruginosa , and Acinetobacter baumannii are the most common Gram-negative bacilli to cause nosocomial infections throughout the world. Due to their large public health and societal implications, carbapenem-r…
View article: In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China Open
To evaluate in vitro antibacterial activity of MRX-8 against gram-negative bacteria recently isolated from China, 765 clinical isolates were collected randomly from 2017 to 2020, including Enterobacterales and P. aeruginosa and A. baumanni…
View article: <i>In Vitro</i> Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China
<i>In Vitro</i> Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China Open
It is reported that A. baumannii has emerged as an intractable nosocomial pathogen in hospitals especially when it develops resistance to carbapenems and other antibiotics, which limits treatment options and leads to high mortality. In Feb…
View article: Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against <i>Enterobacterales</i> Clinical Isolates
Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against <i>Enterobacterales</i> Clinical Isolates Open
Multidrug-resistant Gram-negative bacteria, especially for extended-spectrum β-lactamases-producing and carbapenemase-producing Enterobacterales , are disseminating rapidly around the world. Treatment options for these infections are limit…
View article: A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia
A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia Open
To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). This is a multicenter, randomized, open-label, positive-controlled clinical trial…
View article: A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia
A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia Open
To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). This is a multicenter, randomized, open-label, positive-controlled clinical trial…
View article: A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia
A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia Open
To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). This is a multicenter, randomized, open-label, positive-controlled clinical trial…
View article: Multicenter Clinical Investigation of Vancomycin-resistant Enterococcus Infection
Multicenter Clinical Investigation of Vancomycin-resistant Enterococcus Infection Open
Background: To understand the clinical characteristics of vancomycin-resistant Enterococcus (VRE) infection. Methods: The clinical characteristics of patients with VRE infection, members of CHINET Bacterial Drug Resistance Monitoring Netwo…
View article: <i>In Vitro</i> Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of <i>Enterobacterales</i> , Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018
<i>In Vitro</i> Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of <i>Enterobacterales</i> , Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018 Open
This study evaluated the in vitro activity of cefepime-zidebactam in comparison with that of ceftazidime-avibactam and other comparators against clinically significant Gram-negative bacillus isolates. A total of 3,400 nonduplicate Gram-neg…
View article: Comparative <i>In Vitro</i> Activities of Ceftaroline and Tedizolid against Clinical Strains of Staphylococcus aureus and <i>Enterococcus</i> : Results from the China Antimicrobial Surveillance Network (CHINET) in 2018
Comparative <i>In Vitro</i> Activities of Ceftaroline and Tedizolid against Clinical Strains of Staphylococcus aureus and <i>Enterococcus</i> : Results from the China Antimicrobial Surveillance Network (CHINET) in 2018 Open
The in vitro activities of ceftaroline and tedizolid were compared against Staphylococcus aureus , Enterococcus faecalis , and Enterococcus faecium clinical isolates collected from the China Antimicrobial Surveillance Network. Ceftaroline …
View article: CHINET efforts to control antimicrobial resistance in China
CHINET efforts to control antimicrobial resistance in China Open
View article: 2478. Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018
2478. Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018 Open
Background To investigate the current state of antibacterial resistance of clinical isolates from hospitals in Shanghai, China. Methods Antimicrobial susceptibility testing (AST) was carried out for the clinical isolates from 50 hospitals …
View article: 697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) Open
Background Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-po…
View article: 576. A Multicenter Epidemiology Study on Risk Factors of Vancomycin-Resistant Enterococcus Infections in China: Results from the China Antimicrobial Surveillance Network (CHINET) in 2016
576. A Multicenter Epidemiology Study on Risk Factors of Vancomycin-Resistant Enterococcus Infections in China: Results from the China Antimicrobial Surveillance Network (CHINET) in 2016 Open
Background Bacterial resistance in China had been increasing in prevalence. Vancomycin-resistant enterococcus (VRE) different from other bacteria had lower isolated rate and apparent regional variations. In this study, we identified the ch…
View article: 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) Open
Background Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-po…
View article: Evaluation study of using ampicillin susceptibility to predict imipenem susceptibility of E. faecalis and E. faecium
Evaluation study of using ampicillin susceptibility to predict imipenem susceptibility of E. faecalis and E. faecium Open
Objective: To evaluate ampicillin to predict activity of Enterococcus faecalis and Enterococcus faecium to imipenem. Methods: A total of 127 non-duplicated strains of Enterococcus faecalis and 124 strains of Enterococcus faecium were colle…
View article: Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the <i>In Vitro</i> Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i>
Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the <i>In Vitro</i> Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> Open
The in vitro activities of ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C-T), and comparators were determined for 1,774 isolates of Enterobacteriaceae and 524 isolates of Pseudomonas aeruginosa collected by 30 medical centers from …
View article: In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae Open
Background In recent years, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) infections has increased rapidly. Since the CRE strain is usually resistant to most of antimicrobial agents, patients with this infection are often …